Could stem cells step in to replace lost neurons in Parkinson’s disease? In three Phase 1 clinical trials, scientists tested lab-grown dopaminergic cells in small cohorts to assess safety and look for ...

In the Alzheimer’s brain, microglia diversify into several activation states. What controls this specialization? In a preprint posted to bioRxiv on October 13, scientists led by Martin Kampmann at the ...

Retrotransposons are evolutionarily ancient genes that “jump” around the human genome leaving a slew of repeat nucleotide sequences in their wake. These repeats can disturb normal gene function.

Sensory Stimulation Systems, and GENUS, refer to a noninvasive procedure, i.e., a "digital therapeutic," being developed by Cognito Therapeutics. The company developed a wearable GammaSense ...

Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease pathology with remarkable accuracy (see Part 7 of this series). How ...

For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical practice. Now, they are on the cusp. At this year’s ADPD conference, held ...

This letter was prompted by your recent perspective paper and the responses it provoked in an Alzforum discussion. Generally, my comments are offered with the intellectual humility required when ...

A top researcher’s fall from grace sends shock waves through the scientific community. Such is the case with neuropathologist Eliezer Masliah, who stands accused of image falsification spanning 26 ...

As amyloid immunotherapy is being rolled out, mostly in specialty care thus far, both treating physicians and researchers have many questions about it. Scientists at the Alzheimer’s Association ...

Today the U.S. Food and Drug Administration’s advisory committee gave the nod to donanemab, clearing the way for its marketing approval. All 11 members voted that the antibody was effective for people ...

For 30 years, APOE4 has ranked as the strongest genetic risk factor for Alzheimer’s disease, with two copies boosting the odds up to 15-fold. Now, scientists argue that people with two APOE4 alleles ...